Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Divozilimab Extension Study in Multiple Sclerosis
NCT06987851Phase 3Completed
- Sponsor
- BIOCAD
- Start
- Mar 2022
- Primary completion
- May 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of Divozilimab in multiple sclerosis (MS), sponsored by BIOCAD. Primary endpoint: Annualized Relapse Rate at 96 weeks. Started Mar 2022; status: completed.
02
Drugs
Divozilimab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT06987851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06987851.